NEPHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
NEPHROS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$3.68+0.03 (+0.82%)
Close on Oct 19, 2026
- Market cap
- $40.89M
- P/E (TTM)
- 23.0
- Dividend yield
- –
Nephros statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Nephros | Industry median |
|---|---|---|
| Market Cap | $39.97M | $230.55M |
| Enterprise Value | $35.27M | $202.97M |
| PE Ratio | 23.00 | 33.40 |
| PS Ratio | 1.93 | 3.11 |
Enterprise value
| Measure | Nephros | Industry median |
|---|---|---|
| EV / Sales | 1.70 | 2.92 |
| EV / EBITDA | 19.97 | 19.86 |
| EV / EBIT | 21.48 | 24.88 |
Income (trailing twelve months)
| Measure | Nephros | Industry median |
|---|---|---|
| Revenue | $20.72M | $102.39M |
| Gross Profit | $12.70M | $60.36M |
| Operating Income | $1.64M | -$4.31M |
| Net Income | $1.74M | -$6.57M |
| EBITDA | $1.77M | -$1.98M |
| EPS (Diluted) | $0.16 | -$0.07 |
Margins
| Measure | Nephros | Industry median |
|---|---|---|
| Gross Margin | 61.3% | 55.1% |
| Operating Margin | 7.92% | -6.04% |
| Profit Margin | 8.38% | -10.5% |
| EBITDA Margin | 8.52% | -2.67% |
Returns
| Measure | Nephros | Industry median |
|---|---|---|
| Return on Assets (ROA) | 12.4% | -13.3% |
| Return on Capital Employed (ROCE) | 13.2% | -9.07% |
Growth
| Measure | Nephros | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 24.2% | 8.85% |
| Net Income Growth (YoY) | 30.8% | 10.6% |
| EPS Growth (YoY) | 33.3% | 10.6% |
| Revenue Growth (3Y CAGR) | 23.5% | 7.08% |
| Revenue Growth (5Y CAGR) | 17.0% | 11.8% |
Balance sheet
| Measure | Nephros | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.70M | $37.33M |
| Net Cash (Debt) | $4.70M | $3.92M |
| Net Cash Per Share | $0.43 | $0.28 |
| Working Capital | $10.25M | $54.64M |
Financial position
| Measure | Nephros | Industry median |
|---|---|---|
| Current Ratio | 4.07 | 2.50 |
| Quick Ratio | 2.63 | 1.54 |
Cash flow (trailing twelve months)
| Measure | Nephros | Industry median |
|---|---|---|
| Operating Cash Flow | -$706.00K | -$653.46K |
Efficiency
| Measure | Nephros | Industry median |
|---|---|---|
| Asset Turnover | 1.48 | 0.59 |
| Inventory Turnover | 2.37 | 2.21 |
| Revenue Per Employee | $575.61K | $322.57K |
| Profits Per Employee | $48.22K | -$51.88K |
| Employee Count | 36 | 185 |
Dividends and yields
| Measure | Nephros | Industry median |
|---|---|---|
| Earnings Yield | 4.34% | -6.91% |
Shares
| Measure | Nephros | Industry median |
|---|---|---|
| Shares Outstanding | 10,860,100 | 44,856,700 |
| Shares Change (YoY) | 3.77% | 3.35% |
| Shares Change (QoQ) | 0.15% | 0.27% |
| Float | 9,859,020 | 37,097,900 |
| Shares Held by Insiders | 9.22% | 10.6% |
| Shares Held by Institutions | 48.9% | 63.5% |
Taxes
| Measure | Nephros | Industry median |
|---|---|---|
| Income Tax | $16.00K | $1.52M |
Scores
| Measure | Nephros | Industry median |
|---|---|---|
| Altman Z-Score | -3.84 | 1.95 |
| Piotroski F-Score | 7 | 5 |
| Beneish M-Score | -2.59 | -2.64 |
Calculated by StockData from Nephros's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.